To match an exact phrase, use quotation marks around the search term. eg. "Parliamentary Estate". Use "OR" or "AND" as link words to form more complex queries.

Keep yourself up-to-date with the latest developments by exploring our subscription options to receive notifications direct to your inbox

Speech in Commons Chamber - Tue 14 Apr 2026
Infected Blood Compensation Scheme

"Over the past 21 months, the Minister has worked tirelessly to try to build on the consensus across the House on the legislation that I put through on 21 May 2024 in order to make the scheme work, and I pay tribute to the work he has done. He has …..."
John Glen - View Speech

View all John Glen (Con - Salisbury) contributions to the debate on: Infected Blood Compensation Scheme
Division Vote (Commons)
14 Apr 2026 - Crime and Policing Bill - View Vote Context
John Glen (Con) voted No - in line with the party majority and against the House
One of 90 Conservative No votes vs 0 Conservative Aye votes
Vote Tally: Ayes - 307 Noes - 176
Speech in Commons Chamber - Mon 13 Apr 2026
SEND Provision and Reform

"When addressing this subject, I think of the 16 years of surgeries I have had where parents have come in to explain their profound dissatisfaction with the way in which the evaluation of their child’s needs has been conducted. One of the most powerful examples was a constituent who came …..."
John Glen - View Speech

View all John Glen (Con - Salisbury) contributions to the debate on: SEND Provision and Reform
Speech in Commons Chamber - Mon 13 Apr 2026
SEND Provision and Reform

"I do, but I want to address the key point that I think we all have to acknowledge. Between 2014 and 2023, there was a 140% expansion in the number of EHCPs to well over half a million. In generating that volume of demand, Members in all parts of the …..."
John Glen - View Speech

View all John Glen (Con - Salisbury) contributions to the debate on: SEND Provision and Reform
Speech in Commons Chamber - Mon 13 Apr 2026
SEND Provision and Reform

"Of course I do. This is where the problem is. If we move towards a standardised provision that is driven by central Government or a latest orthodoxy, we risk missing the flexibility that should and needs to exist on an individual basis.

There is a core point about which I …..."
John Glen - View Speech

View all John Glen (Con - Salisbury) contributions to the debate on: SEND Provision and Reform
Speech in Commons Chamber - Mon 13 Apr 2026
SEND Provision and Reform

"I will not have any more time, so I will not.

Let us not peddle a dishonesty by saying that we are going to deliver a perfect system. Frankly, we have got to the point where we need to look at the definitional parameters and get to a more honest …..."
John Glen - View Speech

View all John Glen (Con - Salisbury) contributions to the debate on: SEND Provision and Reform
Speech in Commons Chamber - Mon 13 Apr 2026
SEND Provision and Reform

"The hon. Gentleman is making a very moving and powerful speech, but is not the reality that if every single EHCP was properly diagnosed and the need expressed, it would impose an honest but unachievable burden on the state? Will he acknowledge that and address how we come to terms …..."
John Glen - View Speech

View all John Glen (Con - Salisbury) contributions to the debate on: SEND Provision and Reform
Speech in Commons Chamber - Mon 13 Apr 2026
SEND Provision and Reform

"If we now have a more sophisticated understanding of an individual’s need, and if the provision required to meet that need across society has reached a cost and breadth that is so significant, how do we provide for that given the finite budgets that exist?..."
John Glen - View Speech

View all John Glen (Con - Salisbury) contributions to the debate on: SEND Provision and Reform
Written Question
Office for Budget Responsibility: Research
Tuesday 31st March 2026

Asked by: John Glen (Conservative - Salisbury)

Question to the HM Treasury:

To ask the Chancellor of the Exchequer, when she expects the Office for Budget Responsibility to publish its first set of areas of research interest, as stated in the Economic and Fiscal Outlook - November 2025, published on 26 November 2025.

Answered by Torsten Bell - Parliamentary Secretary (HM Treasury)

The Office for Budget Responsibility (OBR) has full discretion over the timing of its own publication programme.

Written Question
NHS: Drugs
Monday 30th March 2026

Asked by: John Glen (Conservative - Salisbury)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what progress has been made by his Department in encouraging more reclassification applications to the Medicines and Healthcare products Regulatory Agency (MHRA); whether reclassification applications will form part of the MHRA's forthcoming strategy; and what assessment he has made of the potential impact of reclassification applications on (a) the NHS, (b) patients and (c) the Exchequer.

Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)

The Government supports the reclassification of medicines where it is safe and appropriate to do so, as this can improve patient access and support selfcare while maintaining high standards of public health protection. The Medicines and Healthcare products Regulatory Agency (MHRA) actively engages with industry to encourage well evidenced reclassification applications and has updated its guidance and processes to provide greater clarity and efficiency.

Reclassification forms part of the MHRA’s wider strategic work to support proportionate regulation and improve access to medicines, including through closer engagement with industry and the use of scientific advice to support high quality applications.

Where successful, reclassification can benefit the National Health Service by reducing pressure on primary care services, enable patients to access appropriate treatments more conveniently through pharmacies or over the counter supply, and deliver wider economic benefits by supporting selfcare and reducing unnecessary healthcare utilisation. Each application is assessed on its individual merits to ensure that any reclassification maintains patient safety and delivers overall public benefit.

However, reclassification is not appropriate in all circumstances. In particular, where the need for ongoing clinical oversight remains important, or where cost or ability to pay could create barriers to equitable access for some patients, prescription supply through the NHS may remain the most appropriate route. Consideration of patient affordability and health inequalities forms part of the overall assessment of whether reclassification is in the public interest.